Lates News

According to the AI Fast News, China Post Securities issued a research report on April 17, giving a "buy" rating to Zhaoyan Pharmaceutical (603127.SH). The reasons for the rating mainly include: 1) Order backlog reaching a historical high, laying a foundation for performance turnaround; 2) Technological breakthroughs, expansion of qualification and capacity, building long-term competitive moats. (Daily Economic News)